查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012517

解剖學和病理學市場：按產品、技術、應用和最終用戶分類－2026年至2032年全球市場預測

Anatomic Pathology Market by Product, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，解剖學和病理學市場價值將達到 397.8 億美元，到 2026 年將成長到 428.3 億美元，到 2032 年將達到 673.1 億美元，複合年成長率為 7.80%。

主要市場統計數據
基準年 2025 397.8億美元
預計年份：2026年 428.3億美元
預測年份 2032 673.1億美元
複合年成長率 (%) 7.80%

簡要概述技術融合和臨床需求如何重塑解剖病理學的實踐以及相關人員的策略重點。

解剖病理學處於組織學、分子科學和數位創新的交匯點，其在診斷、研究和治療中不斷演變的作用持續改變全球的臨床工作流程。本實施執行摘要的範圍和意圖，重點關注關鍵的變革促進因素、數位和分子模式的融合，以及檢查室和醫療保健系統面臨的營運需求。後續分析旨在整合技術進步、監管影響和商業性趨勢，這些內容對於評估投資、夥伴關係和能力建構的決策者至關重要。

對重塑解剖病理學的關鍵趨勢進行詳細分析，包括數位化整合、分子整合和營運現代化。

在技​​術成熟、勞動力趨勢以及支付方和監管環境變化的推動下，解剖病理學領域正經歷著一場變革。數位病理學正從一項小眾功能發展成為一個實用的平台，用於遠端會診、工作流程標準化和基於影像的決策支持，從而提升了互通性和安全資料儲存的價值。同時，分子診斷和先進的原位技術使得在組織層面進行更詳細的生物學表徵成為可能，為個人化醫療和伴隨診斷開闢了新的途徑。這些變化並非孤立存在，而是相互作用、協同增效，因此，能夠整合和協調來自不同來源的數據的高度適應性實驗室資訊系統和整合軟體顯得尤為重要。

對近期關稅變化如何影響病理檢測領域的採購韌性、供應商策略和營運連續性進行全面考察。

貿易政策的調整將對關鍵檢查室設備和試劑的籌資策略、資本規劃和供應鏈韌性產生重大影響。近期關稅的變化以及由此產生的監管和行政措施，為現有的採購管道帶來了摩擦，影響了前置作業時間、供應商選擇和庫存管理。在此背景下，採購團隊需要重新審視供應商多元化策略，在可行的情況下評估回流和近岸外包方案，並實施能夠應對關稅和海關成本波動的動態採購合約。此外，製造商和分銷商也需要審查定價策略和合約條款，以確保臨床客戶的透明度和連續性。

策略性細分洞察揭示了產品、技術、應用和最終用戶趨勢，從而指導解剖病理學領域的投資和採用路徑。

對產品類型的詳細分析清楚地揭示了臨床和商業性機會的交匯點。儀器、試劑和耗材、服務以及軟體解決方案在提供診斷價值和改善工作流程方面各自發揮獨特的作用。儀器為玻片製作、成像和分子檢測提供物理平台，而試劑和耗材則用於常規診斷和特殊檢測，通常會影響結果的可重複性和分析靈敏度。服務涵蓋安裝、維護和檢查室外包契約，而軟體解決方案則日益發揮「連接組織」的作用，整合資料流、實現品管並支援監管文件編制。

從區域觀點詳細分析基礎設施、法規和臨床需求的地理差異如何影響病理診斷的採用和策略。

區域趨勢影響臨床重點、報銷機制和基礎建設，進而塑造創新在不同地區的發展路徑。在美洲，成熟的檢查室網路和對精準腫瘤學的重視推動了對整合式數位化和分子解決方案的需求，而大規模參考實驗室則在促進整合和標準化工作。該地區的監管路徑和支付模式也鼓勵產生可驗證的臨床效用和真實世界數據（REW），這些數據指導著技術應用和商業化指南。

提供可操作的競爭格局洞察，重點介紹整合供應商、專家創新者和服務合作夥伴在推動解剖病理學發展中的作用。

解剖病理學領域的競爭格局由垂直整合的診斷服務提供者、專注於影像和分子工具的供應商以及新興的軟體和人工智慧 (AI) 公司組成。成熟的儀器和試劑製造商憑藉其規模和監管合規經驗，持續推動臨床應用的廣泛普及。同時，靈活的細分市場企業透過針對特定挑戰的專用檢測、工作流程自動化或分析平台，實現差異化競爭。儀器製造商和軟體供應商之間的夥伴關係與策略聯盟日益普遍，反映出市場對兼具硬體可靠性和先進數據處理能力的端到端解決方案的需求。

為組織領導者提供切實有效的建議，以確保在病理實踐中永續地採用數位化、分子化和自動化策略。

產業領導者應優先考慮能夠平衡短期臨床需求與長期策略能力建構的投資。首先，數位化舉措應以生態系統而非孤立解決方案的方式進行規劃，確保切片掃描、軟體、儲存和服務協同運作，從而實現可衡量的工作流程改進並促進臨床醫生採用。其次，他們應投資模組化自動化，以解決人才短缺問題並提高處理能力，同時確保診斷品質不受影響。自動化決策應基於檢驗研究和綜合培訓計劃，以加速應用。第三，應透過採購多元化、策略性庫存管理和合約機制來增強供應鏈韌性，從而減輕關稅和物流波動的影響。

我們將公開透明地解釋我們的混合方法研究途徑，該方法結合了專家訪談、文獻整合和迭代檢驗，以確保研究結果的穩健性和可靠性。

本執行摘要的研究結合了定性專家對話、多方面文獻整合和結構化檢驗，以得出平衡的見解。主要研究包括對實驗室主任、臨床病理學家、採購經理和行業高管的訪談，以獲取關於技術應用挑戰、臨床優先事項和採購決策者的第一手觀點。這些對話揭示了關鍵主題，並有助於突顯營運限制、監管考量和技術接受因素，而這些因素並非總能在公開文件中體現。

簡要總結了實現綜合性、數據驅動的病理診斷能力所面臨的策略挑戰和機會。

總之，解剖病理學正在向一個整合的、數據驅動的診斷生態系統轉型，該系統將傳統組織病理學與分子和數位技術相結合。這種技術的融合為提高診斷準確性、簡化工作流程和擴大專家知識的獲取途徑提供了明確的機會。然而，要充分發揮這些潛力，需要認真考慮互通性、人才培養、供應鏈韌性以及產生支持臨床和經濟價值的證據。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 解剖病理學市場：依產品分類

  • 裝置
  • 試劑和耗材
  • 服務
  • 軟體解決方案

第9章 解剖病理學市場：依技術分類

  • 數位病理學
    • 服務
    • 幻燈片掃描儀
    • 軟體解決方案
    • 儲存解決方案
  • 免疫組織化學
  • 原位雜合反應
  • 分子診斷
  • 特殊染色

第10章 解剖病理學市場：依應用領域分類

  • 癌症診斷
  • 遺傳性疾病
  • 感染疾病

第11章 解剖學和病理學市場：按最終用戶分類

  • 學術和研究機構
  • 診斷檢測實驗室
  • 醫院
  • 製藥和生物技術公司

第12章 解剖學和病理學市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 解剖學和病理學市場：按組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 解剖學和病理學市場：按國家/地區分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國：解剖學與病理學市場

第16章 中國：解剖病理學市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Cardinal Health, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd
  • Hologic, Inc.
  • Laboratory Corporation of America Holdings
  • NeoGenomics Laboratories, Inc.
  • PerkinElmer, Inc.
  • PHC Holdings Corporation
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Sakura Finetek USA, Inc.
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-431F213C9077

The Anatomic Pathology Market was valued at USD 39.78 billion in 2025 and is projected to grow to USD 42.83 billion in 2026, with a CAGR of 7.80%, reaching USD 67.31 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 39.78 billion
Estimated Year [2026] USD 42.83 billion
Forecast Year [2032] USD 67.31 billion
CAGR (%) 7.80%

Concise orientation explaining how converging technologies and clinical demands are reshaping anatomic pathology practices and strategic priorities for stakeholders

Anatomic pathology sits at the intersection of histology, molecular science, and digital innovation, and its evolving roles in diagnostics, research, and therapeutics continue to reshape clinical workflows worldwide. This introduction presents the scope and intent of the executive summary, highlighting core drivers of change, the convergence of digital and molecular modalities, and the operational demands facing laboratories and health systems. It positions the subsequent analysis as a synthesis of technological advances, regulatory influences, and commercial dynamics that are most relevant to decision-makers evaluating investments, partnerships, and capability expansion.

The field's trajectory is characterized by deeper integration of image analytics and molecular assays with traditional staining and microscopy practices. As a result, laboratories must reconcile legacy processes with opportunities for automation, data interoperability, and augmented diagnostic accuracy. This introduction therefore frames the narrative for stakeholders who require a concise, evidence-informed perspective on how to prioritize investments, manage risk, and accelerate implementation of high-impact technologies. It also establishes the lens through which the report examines segmentation, regional differences, competitive positioning, and actionable recommendations for industry leaders.

Detailed analysis of the major transformative trends reshaping anatomic pathology including digital convergence, molecular integration, and operational modernization

The anatomic pathology landscape is undergoing transformative shifts driven by technological maturation, workforce dynamics, and changing payer and regulatory environments. Digital pathology has progressed from a niche capability to a pragmatic platform for remote consultation, workflow standardization, and image-based decision support, which in turn amplifies the value of interoperability and secure data storage. Concurrently, molecular diagnostics and advanced in situ techniques are enabling richer biologic characterization at the tissue level, creating new pathways for personalized medicine and companion diagnostics. These shifts are not isolated; they interact and compound one another, elevating the importance of adaptable laboratory information systems and integrated software that can orchestrate data from diverse sources.

Operationally, laboratories are balancing the push for throughput and turnaround time with the need to maintain diagnostic quality and regulatory compliance. Workforce shortages and evolving competency requirements necessitate investments in automation, remote collaboration tools, and training programs that can preserve institutional expertise while increasing capacity. Financially, capital allocation decisions are increasingly influenced by demonstrable clinical utility, reimbursement pathways, and measurable workflow efficiencies. Taken together, these transformative changes call for a strategic approach that addresses technology interoperability, change management, and evidence generation to support sustained adoption and clinical impact.

Comprehensive examination of how recent tariff changes reshape procurement resilience, supplier strategies, and operational continuity in anatomic pathology settings

Trade policy adjustments can materially affect procurement strategies, capital planning, and supply chain resilience for laboratory-critical equipment and reagents. Recent tariff changes and the attendant regulatory and administrative measures have introduced friction into established sourcing channels, with implications for lead times, vendor selection, and inventory management. This environment requires procurement teams to reassess supplier diversification, to evaluate reshoring or nearshoring options where feasible, and to implement dynamic purchasing contracts that can absorb variations in duties and clearance costs. In addition, manufacturers and distributors must revisit pricing strategies and contractual terms to ensure transparency and continuity for clinical customers.

From a planning perspective, health systems and commercial laboratories are advised to increase inventory visibility and to formalize contingency protocols for high-impact items. Capital acquisition timelines should incorporate potential delays related to customs and logistics, while clinical operations should identify alternative reagent or instrument options that maintain analytical performance. Regulatory documentation and validation plans may also need updating when equipment models or reagent sources change. Ultimately, an adaptable approach that combines supply chain risk assessment, contractual safeguards, and proactive stakeholder communication will mitigate operational disruption and preserve diagnostic continuity in the face of tariff-driven uncertainty.

Strategic segmentation insights illuminating product, technology, application, and end-user dynamics that guide investment and adoption pathways in anatomic pathology

A nuanced view of product categories clarifies where clinical and commercial opportunities intersect. Instruments, reagents and consumables, services, and software solutions each play distinct roles in delivering diagnostic value and enabling workflow improvements. Instruments provide the physical platforms for slide preparation, imaging, and molecular testing, while reagents and consumables are consumed in routine diagnostics and specialized assays, often dictating repeatability and analytical sensitivity. Services span installation, maintenance, and laboratory outsourcing arrangements, and software solutions increasingly act as the connective tissue that integrates data streams, enables quality control, and supports regulatory documentation.

Technology segmentation reveals differentiated adoption curves and value propositions. Digital pathology emerges as a composite category encompassing services, slide scanners, software solutions, and storage solutions, each component necessary for a functional and scalable digital workflow. Immunohistochemistry and special staining remain foundational for morphological and protein expression analyses, providing established diagnostic context for many disease indications. In situ hybridization and molecular diagnostics expand the diagnostic palette, offering nucleic acid-level insights that complement histomorphology. The interplay between these technologies informs product development priorities and integration strategies.

Application-focused insights show that cancer diagnostics continues to drive demand for high-resolution imaging and multiplexed molecular assays, while genetic disorder testing and infectious disease applications require tailored workflows that balance sensitivity, specificity, and throughput. End-user segmentation highlights distinct purchasing behaviors and implementation timelines across academic and research institutes, diagnostic laboratories, hospitals, and pharmaceuticals and biotechnology companies, each setting presenting specific regulatory, operational, and evidence requirements that influence technology adoption and commercial engagement strategies.

In-depth regional perspective on how geographic differences in infrastructure, regulation, and clinical demand influence anatomic pathology adoption and strategy

Regional dynamics influence clinical priorities, reimbursement mechanisms, and infrastructure readiness, shaping how innovations are deployed across geographies. In the Americas, established laboratory networks and a strong emphasis on precision oncology create demand for integrated digital and molecular solutions, while large reference laboratories drive consolidation and standardization efforts. Regulatory pathways and payer models in this region also incentivize demonstrable clinical utility and real-world evidence generation, which informs adoption pacing and commercialization planning.

The Europe, Middle East & Africa region presents a heterogeneous landscape where high-capability centers coexist with resource-constrained settings; this variance drives demand for scalable solutions that can operate across differing infrastructure levels. Cross-border collaboration and pan-regional reference services are becoming more common, supported by digital pathology and teleconsultation, which helps optimize specialist access and case distribution. Region-specific regulatory frameworks and reimbursement practices require tailored market access strategies and evidence dossiers.

In Asia-Pacific, rapid investments in healthcare infrastructure and an expanding clinical research base are accelerating uptake of advanced pathology technologies, but adoption rates vary by country and by health system maturity. Local manufacturing and distribution partnerships can be critical to navigate import regulations and achieve cost-effective deployment. Across all regions, cross-cutting themes include the need for data governance frameworks, investments in workforce training, and the creation of interoperable systems that support multi-site collaboration and scalable deployment of new diagnostic capabilities.

Actionable competitive landscape insights highlighting the roles of integrated suppliers, specialized innovators, and service partners in anatomic pathology advancement

Competitive dynamics in anatomic pathology are characterized by a mix of vertically integrated diagnostics providers, specialized vendors focused on imaging or molecular tools, and emerging software and artificial intelligence companies. Established instrument and reagent manufacturers continue to leverage scale and regulatory experience to support broad clinical deployments, while nimble niche players differentiate through specialized assays, workflow automation, or analytic platforms that address specific pain points. Partnerships and strategic alliances between instrument makers and software vendors are increasingly common, reflecting the market's need for end-to-end solutions that combine hardware robustness with advanced data processing.

Service providers, including third-party pathology networks and contract laboratory organizations, play a critical role in enabling access to sophisticated testing and in providing implementation expertise. Similarly, companies that offer validation and regulatory consulting are pivotal when customers navigate complex approval pathways and quality system requirements. The competitive landscape rewards firms that can demonstrate interoperability, strong post-market support, and clear pathways for clinical integration, particularly where evidence of diagnostic utility and workflow efficiency are accessible. For purchasers, vendor selection increasingly prioritizes ecosystem compatibility, long-term product roadmaps, and the availability of scalable support services that align with institutional goals.

Practical, high-impact recommendations for organizational leaders to enable sustainable adoption of digital, molecular, and automation strategies in pathology operations

Industry leaders should prioritize investments that balance near-term clinical needs with long-term strategic capability building. First, ensure that digital initiatives are planned as ecosystems rather than point solutions, where slide scanning, software, storage, and services are aligned to deliver measurable workflow improvements and clinician adoption. Second, invest in modular automation to address workforce constraints and to improve throughput without compromising diagnostic quality; automation decisions should be informed by validation studies and integrated training programs to accelerate uptake. Third, strengthen supply chain resilience through diversified sourcing, strategic inventory management, and contractual mechanisms that mitigate tariff and logistics volatility.

Leaders should also focus on evidence generation that demonstrates clinical utility and cost-effectiveness for new assays and platforms, leveraging partnerships with clinical investigators and health economics teams to build robust use-case documentation. In parallel, adopt a phased change-management strategy that includes pilot implementations, local champions, and continuous feedback loops to refine workflows. Finally, build interoperability and data governance capabilities to enable secure multi-site collaboration, AI integration, and compliance with evolving privacy regulations. These priorities will help organizations convert technological potential into sustainable clinical and operational benefits.

Transparent description of a mixed-methods research approach combining expert interviews, literature synthesis, and iterative validation to ensure robust and credible findings

The research underpinning this executive summary combined qualitative expert engagement, multi-source literature synthesis, and structured validation to produce balanced insights. Primary research included interviews with laboratory directors, clinical pathologists, procurement leaders, and industry executives to capture first-hand perspectives on adoption challenges, clinical priorities, and procurement decision drivers. These conversations informed key themes and helped surface operational constraints, regulatory considerations, and technology acceptance factors that are not always evident from published materials.

Secondary research involved systematic review of peer-reviewed literature, regulatory guidance, and industry white papers to contextualize technological capabilities and to identify documented clinical outcomes. Findings were triangulated across sources and validated through follow-up expert consultations to ensure consistency and to reconcile divergent viewpoints. Where appropriate, methodological limitations are acknowledged, including variability in public reporting across regions and the rapidly evolving nature of product capabilities and regulatory positions. Throughout the process, emphasis was placed on transparency of assumptions, reproducibility of analytic steps, and the ethical handling of sensitive information gathered during interviews.

Concise conclusion summarizing the strategic imperatives and opportunities for realizing integrated, data-driven anatomic pathology capabilities

In summary, anatomic pathology is transitioning toward integrated, data-driven diagnostic ecosystems that combine traditional histopathology with molecular and digital modalities. The convergence of these technologies offers clear opportunities to enhance diagnostic accuracy, streamline workflows, and expand access to specialist expertise. However, realizing this potential requires thoughtful attention to interoperability, workforce development, supply chain resilience, and evidence generation that supports clinical and economic value.

Stakeholders across academia, clinical laboratories, hospitals, and industry must therefore adopt coordinated strategies that align technology investments with validated clinical use cases and sustainable operational models. By emphasizing scalable architectures, robust validation pathways, and collaborative implementation practices, organizations can navigate regulatory and commercial complexities to deliver tangible improvements in patient care and laboratory efficiency. The outcome of such an approach is a more resilient, adaptable anatomic pathology ecosystem capable of meeting the evolving demands of precision medicine.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anatomic Pathology Market, by Product

  • 8.1. Instruments
  • 8.2. Reagents & Consumables
  • 8.3. Services
  • 8.4. Software Solutions

9. Anatomic Pathology Market, by Technology

  • 9.1. Digital Pathology
    • 9.1.1. Services
    • 9.1.2. Slide Scanners
    • 9.1.3. Software Solutions
    • 9.1.4. Storage Solutions
  • 9.2. Immunohistochemistry
  • 9.3. In Situ Hybridization
  • 9.4. Molecular Diagnostics
  • 9.5. Special Staining

10. Anatomic Pathology Market, by Application

  • 10.1. Cancer Diagnostics
  • 10.2. Genetic Disorders
  • 10.3. Infectious Disease

11. Anatomic Pathology Market, by End User

  • 11.1. Academic & Research Institutes
  • 11.2. Diagnostic Laboratories
  • 11.3. Hospitals
  • 11.4. Pharmaceuticals & Biotechnology Companies

12. Anatomic Pathology Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Anatomic Pathology Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Anatomic Pathology Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Anatomic Pathology Market

16. China Anatomic Pathology Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Agilent Technologies, Inc.
  • 17.7. Becton, Dickinson and Company
  • 17.8. Bio-Rad Laboratories, Inc.
  • 17.9. Cardinal Health, Inc.
  • 17.10. Danaher Corporation
  • 17.11. F. Hoffmann-La Roche Ltd
  • 17.12. Hologic, Inc.
  • 17.13. Laboratory Corporation of America Holdings
  • 17.14. NeoGenomics Laboratories, Inc.
  • 17.15. PerkinElmer, Inc.
  • 17.16. PHC Holdings Corporation
  • 17.17. QIAGEN N.V.
  • 17.18. Quest Diagnostics Incorporated
  • 17.19. Sakura Finetek USA, Inc.
  • 17.20. Siemens Healthineers AG
  • 17.21. Sysmex Corporation
  • 17.22. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANATOMIC PATHOLOGY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANATOMIC PATHOLOGY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ANATOMIC PATHOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ANATOMIC PATHOLOGY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY SOFTWARE SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY SOFTWARE SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY SOFTWARE SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY SLIDE SCANNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY SLIDE SCANNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY SLIDE SCANNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY SOFTWARE SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY SOFTWARE SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY SOFTWARE SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY STORAGE SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY STORAGE SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY STORAGE SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY IN SITU HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY SPECIAL STAINING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY SPECIAL STAINING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY SPECIAL STAINING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY CANCER DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY CANCER DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY CANCER DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY PHARMACEUTICALS & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY PHARMACEUTICALS & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY PHARMACEUTICALS & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS ANATOMIC PATHOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS ANATOMIC PATHOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS ANATOMIC PATHOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS ANATOMIC PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS ANATOMIC PATHOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS ANATOMIC PATHOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA ANATOMIC PATHOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA ANATOMIC PATHOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA ANATOMIC PATHOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA ANATOMIC PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA ANATOMIC PATHOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA ANATOMIC PATHOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA ANATOMIC PATHOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA ANATOMIC PATHOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA ANATOMIC PATHOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA ANATOMIC PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA ANATOMIC PATHOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA ANATOMIC PATHOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE ANATOMIC PATHOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE ANATOMIC PATHOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE ANATOMIC PATHOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE ANATOMIC PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE ANATOMIC PATHOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE ANATOMIC PATHOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST ANATOMIC PATHOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST ANATOMIC PATHOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST ANATOMIC PATHOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST ANATOMIC PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST ANATOMIC PATHOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST ANATOMIC PATHOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA ANATOMIC PATHOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA ANATOMIC PATHOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA ANATOMIC PATHOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA ANATOMIC PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA ANATOMIC PATHOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA ANATOMIC PATHOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC ANATOMIC PATHOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC ANATOMIC PATHOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC ANATOMIC PATHOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC ANATOMIC PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC ANATOMIC PATHOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC ANATOMIC PATHOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN ANATOMIC PATHOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN ANATOMIC PATHOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN ANATOMIC PATHOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN ANATOMIC PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN ANATOMIC PATHOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN ANATOMIC PATHOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. GCC ANATOMIC PATHOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GCC ANATOMIC PATHOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 125. GCC ANATOMIC PATHOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. GCC ANATOMIC PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. GCC ANATOMIC PATHOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. GCC ANATOMIC PATHOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION ANATOMIC PATHOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION ANATOMIC PATHOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION ANATOMIC PATHOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION ANATOMIC PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION ANATOMIC PATHOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION ANATOMIC PATHOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS ANATOMIC PATHOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS ANATOMIC PATHOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS ANATOMIC PATHOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS ANATOMIC PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS ANATOMIC PATHOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS ANATOMIC PATHOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. G7 ANATOMIC PATHOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. G7 ANATOMIC PATHOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 143. G7 ANATOMIC PATHOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. G7 ANATOMIC PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. G7 ANATOMIC PATHOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. G7 ANATOMIC PATHOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. NATO ANATOMIC PATHOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. NATO ANATOMIC PATHOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 149. NATO ANATOMIC PATHOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 150. NATO ANATOMIC PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. NATO ANATOMIC PATHOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. NATO ANATOMIC PATHOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANATOMIC PATHOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES ANATOMIC PATHOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES ANATOMIC PATHOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES ANATOMIC PATHOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES ANATOMIC PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES ANATOMIC PATHOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES ANATOMIC PATHOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. CHINA ANATOMIC PATHOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA ANATOMIC PATHOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA ANATOMIC PATHOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA ANATOMIC PATHOLOGY MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA ANATOMIC PATHOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA ANATOMIC PATHOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)